PDCD1 and melanoma: A meta-analysis by Jing L et al. has shown that the PD-1 inhibitors can considerably improve the progression-free survival and overall survival in melanoma patients (HR = 0.53 95%CI: 0.48–0.59 and HR = 0.60 95% CI: 0.53–0.69, respectively) (177).